
Moleculin receives European Medicines Agency approval
Moleculin Biotech, a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) …